In our recent Autism Sequencing Consortium (ASC) study (Satterstrom et al 2020), we show that cohorts ascertained for autism spectrum disorder (ASD) and those ascertained for a broader array of neurodevelopmental disorders (NDDs) differ both in the rate and in the relative distribution of mutations across genes. In secondary analyses, we used a binary classifier to separate the 102 ASD genes that we identified into those more often disrupted in individuals ascertained for ASD versus those more often disrupted in individuals ascertained for NDDs; we refer to these as ASD-predominant (ASDP) and ASDNDD genes, respectively. Protein truncating variants in ASDP genes are more likely to be found in parents, and are more likely to be inherited, consistent with reduced selective pressure acting against disruptive variants in ASDP genes. Moreover, in individuals ascertained for ASD, those harboring ASDNDD gene mutations show, on average, greater delays in walking and lower IQ, when compared to those harboring ASDP gene mutations. The results demonstrate that there will be genes that are more clearly associated with the extremes of a clinical phenotypic spectrum. We suggest that the discovery of genes associated with the extremes of the spectrum will provide further insights into pathways disrupted in ASD, and that such discovery is an important direction for future research. Here, in response to a recent commentary by our esteemed colleagues (Myers et al. 2020), we discuss the ASC findings in greater detail and place our results in the context of future research in ASD.